SYK:NYE-Stryker Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 357.93

Change

+1.78 (+0.50)%

Market Cap

USD 41.39B

Volume

1.11M

Analyst Target

USD 217.70
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Stryker Corp is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.43 (-0.37%)

USD 202.52B
MDT Medtronic PLC

N/A

USD 115.29B
STE STERIS plc

-1.65 (-0.67%)

USD 23.65B
ZBH Zimmer Biomet Holdings Inc

+1.12 (+1.07%)

USD 21.34B
SNN Smith & Nephew SNATS Inc

+0.15 (+0.48%)

USD 13.72B
GMED Globus Medical

-0.31 (-0.44%)

USD 9.39B
BIO Bio-Rad Laboratories Inc

+4.29 (+1.33%)

USD 9.12B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.00B
PEN Penumbra Inc

-13.07 (-6.53%)

USD 7.77B
GKOS Glaukos Corp

+0.01 (+0.01%)

USD 6.94B

ETFs Containing SYK

CIB0:XETRA VanEck Bionic Engineering.. 10.42 % 0.00 %

+0.26 (+1.30%)

USD 6.22M
UMDV:SW iShares US Medical Device.. 10.25 % 0.00 %

N/A

N/A
CYBG:LSE VanEck Bionic Engineering.. 9.94 % 0.00 %

+0.21 (+1.30%)

N/A
CWS AdvisorShares Focused Equ.. 4.26 % 0.68 %

+0.65 (+1.30%)

USD 0.17B
XSFD:LSE Xtrackers S&P Select Fron.. 3.75 % 0.00 %

+0.13 (+1.30%)

USD 0.09B
XSFR:LSE Xtrackers S&P Select Fron.. 3.75 % 0.00 %

+0.50 (+1.30%)

USD 0.09B
DX2Z:XETRA Xtrackers - S&P Select Fr.. 3.75 % 0.00 %

-0.15 (1.30%)

USD 0.10B
GOAI:XETRA Amundi Stoxx Global Artif.. 3.61 % 0.00 %

+0.61 (+1.30%)

USD 0.98B
GOAI:PA Amundi Stoxx Global Artif.. 3.34 % 0.00 %

+0.68 (+1.30%)

USD 0.83B
DRUP GraniteShares ETF Trust -.. 2.55 % 0.00 %

+0.22 (+1.30%)

USD 0.06B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

-0.06 (1.30%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
RING iShares MSCI Global Gold .. 0.00 % 0.39 %

+0.58 (+1.30%)

USD 0.55B
UTRN Vesper U.S. Large Cap Sho.. 0.00 % 0.00 %

+0.28 (+1.30%)

USD 0.02B
GOAI:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.35 (+1.30%)

N/A
TACE 0.00 % 0.00 %

N/A

N/A
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.12 (+1.30%)

USD 0.06B
MHCD:CA Middlefield Healthcare Di.. 0.00 % 0.00 %

+0.05 (+1.30%)

CAD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.53% 71% C- 84% B
Dividend Return 0.53% 57% F 11% F
Total Return 20.06% 71% C- 82% B
Trailing 12 Months  
Capital Gain 26.23% 71% C- 82% B
Dividend Return 1.11% 57% F 15% F
Total Return 27.34% 71% C- 81% B-
Trailing 5 Years  
Capital Gain 62.21% 75% C 74% C
Dividend Return 6.13% 50% F 18% F
Total Return 68.34% 75% C 72% C
Average Annual (5 Year Horizon)  
Capital Gain 13.75% 76% C+ 76% C+
Dividend Return 14.90% 79% B- 75% C
Total Return 1.15% 50% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 21.10% 79% B- 50% F
Risk Adjusted Return 70.59% 97% N/A 86% B+
Market Capitalization 41.39B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.